Peer-influenced content. Sources you trust. No registration required. This is HCN.

Remdesivir Now ‘Standard of Care’ for COVID-19, Fauci Says

Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial.